

United States Patent and Trademark Office

UNITED STATES DEFARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

CONFIRMATION NO. ATTORNEY DOCKET NO. FIRST NAMED INVENTOR APPLICATION NO. FILING DATE 9657 10/520,696 10/19/2005 Francisco Jose Munoz Perez U 015575-8 01/10/2008 EXAMINER LADAS & PARRY PAGE, BRENT T 26 WEST 61ST STREET NEW YORK, NY 10023 ART UNIT PAPER NUMBER 1638 MAIL DATE DELIVERY MODE 01/10/2008 **PAPER**

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
Office Action Summary	10/520,696	MUNOZ PEREZ, FRANCISCO JOSE
	Examiner	Art Unit
	Brent Page	1638
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING ID. - Extensions of time may be available under the provisions of 37 CFR 1, after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statul Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATI .136(a). In no event, however, may a reply be d will apply and will expire SIX (6) MONTHS fr te, cause the application to become ABANDO	ON. e timely filed om the mailing date of this communication. ENED (35 U.S.C. § 133).
Status		
1) ☐ Responsive to communication(s) filed on 21 A 2a) ☐ This action is FINAL. 2b) ☐ This action is FINAL. 2b) ☐ This action is application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matters, p	
Disposition of Claims		
4) Claim(s) 1-36 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-36 are subject to restriction and/or Application Papers 9) The specification is objected to by the Examin 10) The drawing(s) filed on is/ are: a) accompact and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct should be subjected to by the Examin and the correct should be subjected to by the Examin and the correct should be subjected to by the Examin and the correct should be subjected to by the Examin and the correct should be subjected to by the Examin and the correct should be subjected to by the Examin and the correct should be subjected to by the Examin and the correct should be subjected to by the Examin and the correct should be subjected to by the Examin and the correct should be subjected to be subjected to by the Examin and the correct should be subjected to be subjecte	er. cepted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 		
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:	Date

10/520,696 Art Unit: 1638

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-15 and 34-35, drawn to an enzyme and method for obtaining an enzyme.

Group II, claim(s) 16-20, 28-32 and 36, drawn to use of primers and a method of generating a transgenic plant.

Group III, claim(s) 21-27 and 33, drawn to an assay device and use of an enzyme in preparation of an assay device.

The inventions are independent or distinct, each from the other because:

The above groupings share the technical feature of an NPPase. However, this feature is not special because it does not constitute and advance over the prior art. Goldfine et al (US Patent 5968508) disclose a method of neutralizing PC-1 (an NPPase) (see Claims and description of PC-1 7th paragraph, for example).

The inventions are further distinct from one another for the following reasons.

Invention I requires neither the primers of Invention II nor the assay of Invention III to function as an enzyme or for the isolation of said enzyme. Invention I further does not require the assay generating method steps, nor the transgenic plant materials and

10/520,696

Art Unit: 1638

methods of Invention II. Invention I does require protein isolation steps and materials not required by Inventions II or III.

Invention II requires plant materials and methods for the generation of transgenic plants not required by any other invention. Invention II does not require protein isolation materials and methods required by Invention I nor the assay devices required by Invention III.

Invention III requires assay steps and devices not required by any other invention. Invention III does not require the plant materials and method of Invention II, nor the protein isolation steps of Invention I.

For the reasons given above, restriction is proper.

In addition to the above restriction requirement, Applicant is also required to select a single SEQ ID NO: representing the elected invention, (A single SEQ ID NO: representing ONE NPPASE OR ONE NPPASE fragment, or if Applicant elects primers ONE SEQ ID NO representing ONE primer and ONE SEQ ID representing ONE cDNA, Applicant is not entitled to additionally select a sequence unless the sequence falls within the scope of the selected invention. Distinctly different DNA sequences are structurally distinct chemical compounds and are deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

Application/Control Number:

10/520.696

Art Unit: 1638

Applicant is required to elect a Group above representing a single nucleotide sequence. Electing a sequence is not to be construed as a requirement for an election of species, since each nucleotide sequence is not a member of a single genus of invention, but constitutes and independent and patentably distinct invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Application/Control Number:

10/520,696 Art Unit: 1638

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brent Page whose telephone number is (571)-272-5914. The examiner can normally be reached on Monday-Friday 8-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on (571)-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Brent T Page

PHUONG T. BUI PRIMARY EXAMINED